Proposing the Substitute Target Clause Samples

Proposing the Substitute Target. Within 30 days after ▇▇▇▇’ receipt of a Substitute Notice, Isis and AstraZeneca will discuss and mutually agree whether such Proposed Substitute Target will become an Oncology Target. Isis will, within [***] days after ▇▇▇▇’ receipt of any Substitute Notice, inform AstraZeneca of any Target Encumbrances applicable to the Proposed Substitute Target. If ▇▇▇▇ and AstraZeneca mutually agree that the Proposed Substitute Target will become an Oncology Target, then such Proposed Substitute Target (a “Substitute Target”) will become an Oncology Target upon (i) Isis’ receipt of AstraZeneca’s written agreement to be responsible for any payment obligations arising from the Target Encumbrances identified in accordance with this Section 3.3.7(b) (other than Isis Supported Pass-Through Costs) applicable to such Substitute Target and related Products, and (ii) if the Substitute Target is substituted in as an Oncology Target after the Discontinued Target achieved Target Sanction status, Isis’ receipt of the payment in accordance with Section 3.3.7(d) below. For clarity, any Discontinued Target will no longer be an Oncology Target and will therefore no longer be a part of the Oncology Collaboration under this Agreement, and Isis’ obligations and AstraZeneca’s rights under this Agreement with respect to such Discontinued Target (including but not limited to Section 5.1.1) will terminate.